Today: 19 January 2026
Subscribe
Browse Category

Clinical Trials News 23 December 2025 - 2 January 2026

SELLAS (SLS) stock jumps about 10% in premarket as REGAL AML trial milestone stays in focus

SELLAS (SLS) stock jumps about 10% in premarket as REGAL AML trial milestone stays in focus

NEW YORK, January 2, 2026, 05:03 ET — Premarket SELLAS Life Sciences Group (SLS) shares rose about 10% in U.S. premarket trading on Friday to $4.14, after gaining 13.9% in the prior regular session. Early trading ranged between $4.13 and $4.32. Public The move matters because SELLAS’ valuation hinges on a single late-stage cancer study, and timing signals can drive…
2 January 2026
····
Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus

Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus

NEW YORK, December 31, 2025, 09:15 ET — Premarket Ultragenyx Pharmaceutical (RARE.O) shares edged down 0.2% to $22.74 in premarket trading on Wednesday, after finishing Tuesday up 15.5% at $22.78. The stock’s 52-week range is $18.41 to $46.50. StockAnalysis The rare-disease drugmaker is trying to find its footing after a sharp two-day repricing driven by a late-stage clinical setback that…
31 December 2025
···
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key…
30 December 2025
····
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

NEW YORK, December 30, 2025, 02:05 PM ET — Regular session Zenas BioPharma Inc shares fell $2.02, or 5.2%, to $37.03 in afternoon trading on Tuesday, after ending the prior session at $39.05. The stock ranged from $36.94 to $40.50, with about 123,000 shares traded. The drop came as biotech stocks eased in thin year-end trading, with the Nasdaq Biotechnology…
30 December 2025
····
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

NEW YORK, December 30, 2025, 09:17 ET — Premarket Zenas BioPharma, Inc. shares were flat in premarket trading on Tuesday, with the stock last indicated at $39.05 as of 9:00 a.m. ET. The biotech closed down 8.1% on Monday. Public The pause comes at a sensitive point on the calendar for investors: the company has told investors to expect a…
30 December 2025
··
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

NEW YORK, December 30, 2025, 01:49 ET — Market closed SELLAS Life Sciences Group Inc (SLS) shares jumped 16.7% on Monday to close at $3.35 after the company updated investors on the timing of a late-stage acute myeloid leukemia (AML) trial. The stock traded between $2.60 and $3.44 and logged about 22.4 million shares, according to StockAnalysis data. StockAnalysis The…
30 December 2025
····
Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

NEW YORK, December 29, 2025, 23:16 ET — Market closed Mereo BioPharma Group plc shares closed down 87.65% at $0.29 on Monday after the company disclosed late-stage data that failed to hit a key fracture-rate endpoint for setrusumab, its lead rare-disease program. The stock traded between $0.20 and $0.30, with about 241 million shares changing hands, according to the company’s…
30 December 2025
···
Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx Pharmaceutical Inc shares slid on Monday after the company said two late-stage studies of setrusumab for osteogenesis imperfecta missed their primary fracture-reduction goal, prompting plans for significant expense reductions. “We are surprised and disappointed by these results,” Chief Executive Emil Kakkis said. Shares last traded down 42.3% at $19.72 after the close, versus a prior close of $34.19, after…
30 December 2025
···
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

NEW YORK, Dec. 28, 2025, 3:26 p.m. ET — Market closed Johnson & Johnson stock (NYSE: JNJ) heads into the final trading week of 2025 with U.S. markets shut for the weekend and investors sorting through a fresh pipeline headline that surfaced late Friday. With the New York Stock Exchange closed today and the next regular session set for Monday,…
28 December 2025
····
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

NEW YORK, Dec. 27, 2025, 3:33 PM ET — Market closed Johnson & Johnson (NYSE: JNJ) stock is heading into the final trading days of 2025 with U.S. markets closed for the weekend and year-end liquidity typically thinning across Wall Street. JNJ last closed at $207.63 on Friday, down 0.07% on the day, and was last indicated around $207.86 in…
27 December 2025
····
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

NEW YORK — Friday, December 26, 2025 (9:13 a.m. ET): U.S. stocks are heading into a thin, post‑Christmas trading day, with Wall Street set for a relatively muted open as investors digest a strong 2025 tape and look ahead to 2026 rate and earnings narratives. Reuters In that kind of tape, headline-driven biotech names can swing harder than usual—and ABIVAX…
26 December 2025
····
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday, Dec. 23, 2025, SLS stock traded around $2.64, according to market data. In the prior session, the stock closed around…
23 December 2025
····
1 2 3 4 5 … 8

Stock Market Today

  • HOLX vs. SYK: Analyzing Growth Prospects of Medical Devices Leaders Ahead of Earnings
    January 19, 2026, 9:48 AM EST. Hologic (HOLX) and Stryker (SYK) are key U.S. medical device companies positioned for growth amid a projected 6.8% market CAGR by 2032. HOLX, valued at $16.7 billion and undergoing a buyout by Blackstone & TPG, drives innovation in women's health diagnostics and surgical products, recently securing FDA and EU clearances for new assays and diagnostic systems. SYK, with a $139.1 billion market cap, excels across surgical, orthopaedic, and neurotechnology sectors globally. Ahead of their January 29 earnings, HOLX showed strength in molecular diagnostics and surgical product sales, while SYK sustained robust demand across instruments, endoscopy, and emergency care products despite supply-chain challenges. Both firms demonstrate solid revenue drivers, making them central to the evolving medical technology landscape.
Go toTop